文献速递脑血管病

双联抗血小板治疗增加实验性卒中溶栓后出血转化

Dual Antiplatelet Therapy Increases Hemorrhagic Transformation Following Thrombolytic Treatment in Experimental Stroke.
PubMed 文献 · Stroke · 2019-10-07

该研究在雄性C57BL6小鼠中建立双联抗血小板(阿司匹林+氯吡格雷)联合tPA溶栓的实验性卒中模型,发现双抗治疗显著降低血小板功能,tPA溶栓后出血转化面积增加18.9±5.4 mm2(P=0.0045),且降低tPA剂量未能预防出血并发症。

要点

  • 双抗小鼠tPA溶栓后出血转化较对照显著增加18.9±5.4 mm2。
  • 双抗未溶栓小鼠出血转化非显著升高8.0±4.6 mm2。
  • 降低tPA剂量未能减少双抗小鼠的出血转化。

核心结论

  • 双联抗血小板治疗导致血小板功能受损,增加tPA溶栓后出血转化风险。
  • 降低tPA剂量不能预防双抗治疗下的出血并发症。

研究设计与样本

  • 雄性C57BL6小鼠经饮水给予阿司匹林和氯吡格雷3天,随后行2小时短暂大脑中动脉闭塞并输注tPA。
  • 出血转化通过ImageJ测量脑切片出血面积定量,TTC染色测定梗死体积,流式细胞术和尾出血试验评估血小板功能。

主要发现

  • 流式细胞术和尾出血体积均显示双抗治疗后血小板功能显著降低。
  • tPA在MCAO后2小时给药未引起对照小鼠出血(0.51±0.13 mm2),但双抗小鼠出血转化显著增加18.9±5.4 mm2(P=0.0045)。
  • 双抗未溶栓小鼠出血转化较对照非显著升高8.0±4.6 mm2(P=0.3784)。
  • 各组梗死体积无差异。
  • 降低tPA剂量后出血转化持续存在。

临床怎么用

  • 双抗治疗患者接受tPA溶栓时需警惕出血转化风险增加。
  • 降低tPA剂量可能不足以规避双抗相关的出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Dual antiplatelet treatment poses a risk for increased hemorrhagic transformation (HT) following intravenous thrombolysis and mechanical thrombectomy. The aim of this study was to implement a model of experimental stroke with tissue-type plasminogen activator (tPA)-associated HT in mice on dual antiplatelet treatment to enable mechanistic studies and also to allow for an initial assessment of therapeutic approaches to limit HT. Methods- Male C57BL6 mice were fed with Aspirin and Clopidogrel via drinking water for 3 days. Subsequently, mice were subjected to 2-hour transient middle cerebral artery occlusion, and tPA was infused when indicated. HT was quantified by measuring hemorrhaged areas in brain sections with ImageJ. TTC staining was used to determine infarct size. Platelet function was tested in vitro using flow cytometry and in vivo with standard tail bleeding tests. Results- Both flow cytometry and tail bleeding volumes indicated significantly reduced platelet function following Aspirin and Clopidogrel treatment. While tPA administered 2 hours after onset of middle cerebral artery occlusion did not cause bleeding in control mice (0.51±0.13 mm2), HT significantly increased by 18.9±5.4 mm2 (P=0.0045) in Aspirin and Clopidogrel mice treated with tPA. HT in aspirin and clopidogrel mice not treated with tPA was nonsignificantly elevated by 8.0±4.6 mm2 (P=0.3784) compared with controls. Infarct sizes did not differ between groups. The HT persisted when the tPA dosage was reduced. Conclusions- We successfully established a translational stroke model of tPA treatment under dual antiplatelet treatment. The impaired platelet function led to an increased risk for HT in tPA-treated mice. Reducing the dosage of tPA did not prevent this hemorrhagic complication.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Lieschke F, Schaefer JH, et al. Dual Antiplatelet Therapy Increases Hemorrhagic Transformation Following Thrombolytic Treatment in Experimental Stroke. Stroke. 2019. PMID: 31587659. doi:10.1161/STROKEAHA.119.027359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。